Impact of Glucocorticoid Therapy on 28-Day Mortality in Patients Having Severe Fever with Thrombocytopenia Syndrome in an Intensive Care Unit: A Retrospective Analysis
Guangjie Wang,Puhui Liu,Hui Xie,Chuanzhen Niu,Jie Lyu,Youzhong An,Huiying Zhao
DOI: https://doi.org/10.2147/jir.s478520
IF: 4.5
2024-10-24
Journal of Inflammation Research
Abstract:Guangjie Wang, 1, &ast Puhui Liu, 2, &ast Hui Xie, 2 Chuanzhen Niu, 2 Jie Lyu, 1 Youzhong An, 1 Huiying Zhao 1 1 Department of Critical Care Medicine, Peking University People's Hospital, Beijing, People's Republic of China; 2 Department of Critical Care Medicine, Yantai Qishan Hospital, Yantai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Huiying Zhao, Department of Critical Care Medicine, Peking University People's Hospital, No. 11, Southern Xizhimen Road, Beijing, 100044, People's Republic of China, Tel +86 13811088270, Email Purpose: The high mortality rate associated with the critical stages of severe fever with thrombocytopenia syndrome (SFTS) does not have effective treatment. We aimed to evaluate the 28-day mortality and potential impact of glucocorticoid therapy in these patients. Patients and Methods: This retrospective observational study included participants from the intensive care unit between July 2019 and April 2023. The participants were categorized into glucocorticoid (GC) and non-GC groups. Propensity score matching (PSM) was employed to ensure comparability between groups. We used Cox proportional hazard models to examine mortality risk associated with GC use, Kaplan–Meier survival analyses for overall survival, stratified Cox proportional hazard models for subgroup analyses, and likelihood ratio tests to examine interactions between subgroups. Results: Of 218 patients with SFTS (median age, 71 years; male, 49.1%), 61.9% required mechanical ventilation, 58.3% received GC treatment, and the 28-day mortality rate was 61.5%. After PSM, there were 58 patients in each group; post-PSM analysis revealed improved 28-day mortality rates with GC treatment, particularly for patients with Glasgow coma scale (GCS) score < 13 (hazard ratio [HR], 95% confidence interval [CI] for GCS score: 9– 12: 0.39, 0.17– 0.88, p =0.024 and for GCS score: 3– 8: 0.09, 0.02– 0.35, p =0.001); lactate levels > 2 mmol/L (0.35, 0.15– 0.83, p =0.017); and norepinephrine usage (0.26, 0.13– 0.49, p < 0.001). Combining antiviral (0.41, 0.22– 0.78, p =0.006) or immunoglobulin therapy (0.22, 0.1– 0.51, p < 0.001) with GC treatment significantly decreased the 28-day mortality rates, compared with GC monotherapy. Conclusion: Using GCs reduced the high 28-day mortality rate in the patients, especially with low GCS score, high lactate levels, norepinephrine intake, and on antiviral or immunoglobulin therapy. Keywords: glucocorticoids, mortality, severe fever with thrombocytopenia syndrome, intensive care unit, virus infection Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease that affects both humans and animals and is caused by severe fever with thrombocytopenia syndrome virus (SFTSV). The SFTSV was first isolated from a patient's blood sample in Henan province in 2009. 1 The disease is endemic in several Asian countries, including China, Korea, Vietnam, Pakistan, and Japan, and has been shown to cause high mortality rates across these regions. 1–5 The clinical manifestations of SFTSV infection mainly include fever, thrombocytopenia, leukopenia, and gastrointestinal symptoms. Although most patients with SFTSV have mild to moderate symptoms, some may experience severe complications, such as organ failure and blood clotting issues, which can quickly lead to death. 6 Once the central nervous system is involved, the mortality rate can reach 44.7%. 7 For critically ill patients with SFTSV, no effective drug or intervention has been shown to reduce mortality except life support. A severe systemic inflammatory response is one of the primary characteristics of this condition. 8 Consequently, systemic glucocorticoid (GC) therapy serves as an adjunct treatment in patients with severe SFTS in clinical settings. 9–12 However, the effects of GCs on SFTS have been inconsistent across studies, 9,11 suggesting the need to understand the specific circumstances that cause variations in treatment efficacy. Notably, the effect of GC therapy may depend on the severity of patient's condition. Despite the known inconsistencies and the potential impact of patient conditions on therapy outcomes, to the best of our knowledge, no studies have specifically addressed the use of GCs in critically ill patients with SFTS in the intensive care unit (ICU). Therefore, this study aimed to evaluate the 28-day mortality and potential impact of glucocorticoid therapy in these patients. This study employed a retrospective observational -Abstract Truncated-
immunology